These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 18240019)

  • 41. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
    Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Dopazo J; Rivas C; Benítez J
    Breast Cancer Res Treat; 2005 Mar; 90(1):5-14. PubMed ID: 15770521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
    Guler G; Uner A; Guler N; Han SY; Iliopoulos D; Hauck WW; McCue P; Huebner K
    Cancer; 2004 Apr; 100(8):1605-14. PubMed ID: 15073846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP-1 correlates with hormone receptor status but not with local recurrence.
    Millar EK; Tran K; Marr P; Graham PH
    Pathol Int; 2007 Apr; 57(4):183-9. PubMed ID: 17316413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells.
    Freund A; Chauveau C; Brouillet JP; Lucas A; Lacroix M; Licznar A; Vignon F; Lazennec G
    Oncogene; 2003 Jan; 22(2):256-65. PubMed ID: 12527894
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein.
    Kawakubo H; Brachtel E; Hayashida T; Yeo G; Kish J; Muzikansky A; Walden PD; Maheswaran S
    Cancer Res; 2006 Jul; 66(14):7075-82. PubMed ID: 16849553
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.
    Oh DS; Troester MA; Usary J; Hu Z; He X; Fan C; Wu J; Carey LA; Perou CM
    J Clin Oncol; 2006 Apr; 24(11):1656-64. PubMed ID: 16505416
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1.
    Rody A; Holtrich U; Gaetje R; Gehrmann M; Engels K; von Minckwitz G; Loibl S; Diallo-Danebrock R; Ruckhäberle E; Metzler D; Ahr A; Solbach C; Karn T; Kaufmann M
    Clin Cancer Res; 2007 Feb; 13(4):1115-22. PubMed ID: 17317819
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer.
    Lindahl T; Landberg G; Ahlgren J; Nordgren H; Norberg T; Klaar S; Holmberg L; Bergh J
    Carcinogenesis; 2004 Mar; 25(3):375-80. PubMed ID: 14633656
    [TBL] [Abstract][Full Text] [Related]  

  • 49. C-erbB2, p27 and G1/S aberrations in human primary breast cancer.
    Lodén M; Perris F; Nielsen NH; Emdin SO; Landberg G
    Anticancer Res; 2003; 23(3A):2053-61. PubMed ID: 12894578
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Expression of steroid receptors and DNA synthesis in male breast cancer].
    Petroni S; Mangia A; D'Amico C; Simone G
    Pathologica; 2003 Feb; 95(1):31-6. PubMed ID: 12735283
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
    Rody A; Karn T; Ruckhäberle E; Müller V; Gehrmann M; Solbach C; Ahr A; Gätje R; Holtrich U; Kaufmann M
    Breast Cancer Res Treat; 2009 Feb; 113(3):457-66. PubMed ID: 18340528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers--results of a large scale microarray analysis.
    Rody A; Karn T; Ruckhäberle E; Hanker L; Metzler D; Müller V; Solbach C; Ahr A; Gätje R; Holtrich U; Kaufmann M
    Eur J Cancer; 2009 Feb; 45(3):405-13. PubMed ID: 19054665
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Estrogen-induced genes in breast cancer, and their medical importance].
    Rochefort H
    Bull Acad Natl Med; 1999; 183(5):955-68; discussion 968-71. PubMed ID: 10465000
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens.
    Pacilio C; Germano D; Addeo R; Altucci L; Petrizzi VB; Cancemi M; Cicatiello L; Salzano S; Lallemand F; Michalides RJ; Bresciani F; Weisz A
    Cancer Res; 1998 Mar; 58(5):871-6. PubMed ID: 9500441
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
    Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.
    Ahlin C; Lundgren C; Embretsén-Varro E; Jirström K; Blomqvist C; Fjällskog M-
    Breast Cancer Res Treat; 2017 Aug; 164(3):667-678. PubMed ID: 28528450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. C-kit expression in high-risk breast cancer subgroup treated with high-dose or conventional dose-dense chemotherapy.
    Diallo R; Ting E; Gluz O; Herr A; Schütt G; Geddert H; Mohrmann S; Gabbert HE; Nitz U; Poremba C
    Verh Dtsch Ges Pathol; 2006; 90():177-85. PubMed ID: 17867595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
    Jirström K; Stendahl M; Rydén L; Kronblad A; Bendahl PO; Stål O; Landberg G
    Cancer Res; 2005 Sep; 65(17):8009-16. PubMed ID: 16140974
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer.
    Wang Z; Dahiya S; Provencher H; Muir B; Carney E; Coser K; Shioda T; Ma XJ; Sgroi DC
    Clin Cancer Res; 2007 Nov; 13(21):6327-34. PubMed ID: 17975144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.